Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Engineered Extracellular Vesicles in Arthritic Diseases: Therapeutic Applications & Challenges

Ehab S., Gaser OA., Oyouni AAA., Kameli N., Alzahrani F., Abdal Dayem A.

Clinical Trial on Osteoarthritis, Cartilage Damage, Immune Modulation, published in Wiley Interdiscip Rev Nanomed Nanobiotechnol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Wiley Interdiscip Rev Nanomed Nanobiotechnol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40830968
PMCID
PMC12365376
DOI
10.1002/wnan.70031
Citations
2

Abstract (original English)

Arthritic diseases are a significant global health challenge, highlighting the urgent need for innovative therapeutic strategies. Extracellular vesicles (EVs) have emerged as promising candidates for treating various intractable diseases. This review explores the therapeutic potential of engineered EVs in joint diseases, particularly in comparison to their parental stem cells. Recent research underscores the efficacy of EVs in treating joint diseases, especially Osteoarthritis (OA). We discuss EV engineering strategies aimed at overcoming the limitations of natural EVs. Data from preclinical trials, clinical studies, and in vitro and in vivo reports are analyzed to evaluate the effectiveness of EVs in treating joint conditions. In addition to their role in intercellular communication, EVs influence various biological processes crucial for bone remodeling, cartilage regeneration, immunomodulation, and inflammation control. EVs are rich in vital biomolecules such as proteins, microRNAs (miRNA), lipids, and nucleic acids, which enhance their therapeutic potential compared to parental stem cells. This understanding is key to developing targeted and effective engineered EVs for OA and other joint diseases. A comprehensive grasp of EV engineering and underlying mechanisms will pave the way for novel and efficient therapies for arthritic diseases and related conditions. This article i

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsHumansOsteoarthritisExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research